Thelansis

Polymyositis Market Outlook Thelansis’s “Polymyositis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polymyositis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do intervie...

Polymyositis Market Outlook Thelansis’s “Polymyositis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polymyositis     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Polymyositis Overview Polymyositis is characterized by persistent inflammation and muscle weakness affecting the skeletal muscles. Typically, this weakness initially manifests in the proximal muscles, which include those in the upper arm, shoulder, upper leg, and hip. Clinical indicators of polymyositis encompass non-specific symptoms like proximal muscle weakness and increased serum creatine kinase levels. The condition’s onset usually occurs in individuals ...

Polymyositis is characterized by persistent inflammation and muscle weakness affecting the skeletal muscles. Typically, this weakness initially manifests in the proximal muscles, which include those in the upper arm, shoulder, upper leg, and hip. Clinical indicators of polymyositis encompass non-specific symptoms like proximal muscle weakness and increased serum creatine kinase levels. The condition's onset usually occurs in individuals over 20, with most patients falling within the 45 to 60-year range. The disease tends to develop gradually over 3 to 6 months, and its impact on physical capabilities can vary significantly. This may result in difficulties such as lifting objects, raising the arms, kneeling, and ascending and descending stairs. ·        In terms of its prevalence, the estimated annual occurrence of cases ranges between 1.5 to 2.2 cases per 150,000 to 250,000 people, and the overall prevalence falls within the range of 1 to 2 cases per 50,000...

 Polymyositis is characterized by chronic muscle inflammation and weakness involving the skeletal muscles. The weakness generally starts in the proximal muscles, such as muscles of the upper arm and shoulder and the upper leg and hip. Polymyositis has non-specific clinical features, including proximal muscle weakness and elevated serum creatine kinase. The age of onset is over 20 years, with most patients aged 45-60 years. The disease develops gradually over a period of 3 to 6 months with a variable impact on physical capacities: difficulty lifting objects, raising arms, kneeling, and climbing or descending stairs. ·        The estimated annual incidence of cases ranges between 1.5 to 2.2 cases per 150,000 to 250,000 individuals, and the prevalence ranges between 1 to 2 cases per 50,000 individuals. Thelansis’s “Polymyositis Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epi...

  Polymyositis is characterized by chronic muscle inflammation and weakness involving the skeletal muscles and the weakness generally starts in the proximal muscles such as muscles of the upper arm and shoulder and the upper leg and hip. Polymyositis has non-specific clinical features including proximal muscle weakness and elevated serum creatine kinase. The age of onset is over 20 years, with most patients aged 45-60 years. The disease develops gradually over a period of 3 to 6 months with a variable impact on physical capacities: difficulty lifting objects, raising arms, kneeling, and climbing or descending stairs.   ·        Arthralgia may be found and myalgia is reported in less than 30% of patients. Other signs include neck flexor weakness, fatigue, stiffness, weight loss anorexia, dysphagia, and less commonly dysphonia. ·        The estimated annual incidence cases range between 1.5 to 2.2 cases per 150,00...